IE
ARQT icon

Israel Englander’s Arcutis Biotherapeutics ARQT Stock Holding History

Israel Englander’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.8M Buy
564,072
+514,739
+1,043% +$12M 0.01% 1909
2026
Q1 		$1.16M Sell
49,333
-187,437
-79% -$4.78M ﹤0.01% 4283
2025
Q4 		$6.88M Buy
236,770
+86,671
+58% +$2.22M ﹤0.01% 2669
2025
Q3 		$2.83M Sell
150,099
-760,742
-84% -$12M ﹤0.01% 3723
2025
Q2 		$12.8M Buy
910,841
+437,216
+92% +$6.13M 0.01% 2010
2025
Q1 		$7.41M Sell
473,625
-1,836,538
-79% -$25.9M ﹤0.01% 2477
2024
Q4 		$32.2M Buy
2,310,163
+1,162,690
+101% +$12.7M 0.02% 1130
2024
Q3 		$10.7M Buy
1,147,473
+634,777
+124% +$6.26M 0.01% 2145
2024
Q2 		$4.77M Buy
512,696
+133,645
+35% +$1.21M ﹤0.01% 2771
2024
Q1 		$3.76M Sell
379,051
-2,179,829
-85% -$16.3M ﹤0.01% 3162
2023
Q4 		$8.27M Buy
2,558,880
+2,249,931
+728% +$6.12M ﹤0.01% 2350
2023
Q3 		$1.64M Buy
+308,949
New +$2.63M ﹤0.01% 3749
2023
Q1 		– Sell
-664,447
Closed -$9.83M – 6334
2022
Q4 		$9.83M Buy
664,447
+578,550
+674% +$10.1M 0.01% 2137
2022
Q3 		$1.64M Buy
+85,897
New +$1.95M ﹤0.01% 3927
2022
Q2 		– Sell
-100,126
Closed -$1.93M – 6944
2022
Q1 		$1.93M Buy
+100,126
New +$1.69M ﹤0.01% 3924
2021
Q4 		– Sell
-30,618
Closed -$731K – 6752
2021
Q3 		$731K Buy
+30,618
New +$698K ﹤0.01% 4980
2021
Q2 		– Sell
-15,093
Closed -$437K – 6500
2021
Q1 		$437K Sell
15,093
-145,001
-91% -$4.53M ﹤0.01% 4929
2020
Q4 		$4.5M Buy
160,094
+129,452
+422% +$3.17M ﹤0.01% 2551
2020
Q3 		$898 Buy
30,642
+4,703
+18% +$126K ﹤0.01% 3218
2020
Q2 		$784K Buy
25,939
+14,055
+118% +$406K ﹤0.01% 3136
2020
Q1 		$354K Buy
+11,884
New +$319K ﹤0.01% 3077

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Israel Englander's ARQT Position: Q2 2026 in Review

Israel Englander increased its Arcutis Biotherapeutics (ARQT) stake by 1,043% in Q2 2026, buying an estimated $12M and bringing the position to 564,072 shares worth $14.8M. The position accounts for 0.01% of the portfolio, ranked #1909.

Israel Englander first reported a position in ARQT in Q1 2020 and has held it in 21 quarters since. The position peaked at $32.2M in Q4 2024. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Israel Englander held 564,072 shares of Arcutis Biotherapeutics worth $14.8M as of Q2 2026.
  • Israel Englander bought 514,739 Arcutis Biotherapeutics shares in Q2 2026, an estimated $12M.
  • Arcutis Biotherapeutics made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1909 holding.
  • Israel Englander first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 21 quarters since.
  • Israel Englander's Arcutis Biotherapeutics position peaked at $32.2M in Q4 2024.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.